 Cookies help identify the right message.

We would like to use anonymous analytics cookies to help improve our website experience. View our cookie policy.

Skip to content
Pipeline Investors News Join us Contact

Contact Us

  • +44 [0] 20 4551 8888
  • contact@tangramtx.com
  • Tangram Therapeutics on LinkedIn
  • Tangram Therapeutics on X
Tangram Therapeutics | Committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster.
  • About[+]
    • About[+]
      • Why Tangram?Explore more about how and why Tangram Therapeutics exists.
      • LeadershipDiscover the people leading the way in relentless medicine discovery.
  • Pipeline
  • Our science[+]
    • Our Science[+]
      • Our ApproachWe reduce the risks of making impactful medicine a reality.
      • LLibraConnecting extensive data and information with AI, powering GalOmic drug discovery.
      • GalOmicEnabling the generation of Tangram Therapeutics' potent and long-acting RNAi medicines.
  • Investors
  • News
  • Join us
  • Contact
Menu
Press release

e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

1 October 2025

  • Press release

Key Milestone Achieved and Significant Progress on Galapagos Collaboration

Apr 12, 2022

  • Press release

Immuno-Oncology Research Collaboration with iTeos Therapeutics

Apr 5, 2022

  • Press release

Senior Management Update

Nov 22, 2021

  • Press release

RNAi Platform Characterisation Results

Oct 26, 2021

  • Press release

Interim results for six months ended 31 July 2021

Oct 26, 2021

  • Press release

Investor Presentation

Oct 20, 2021

  • Press release

Patent Filing Applications

Oct 11, 2021

  • Press release

Notice of Interim Results

Oct 11, 2021

  • Press release

Commencement of trading on the OTCQX Best Market

Sep 24, 2021

  • Press release

Further milestone in Galapagos collaboration

Jul 2, 2021

  • Press release

Senior Management Appointment and Options Grant

Jun 2, 2021

  • Press release

Results of conditional Fundraise to raise £22.5 million

May 14, 2021

  • Press release

Proposed Fundraise in excess of £20 million

May 13, 2021

  • Press release

Retail Offer

May 13, 2021

  • Press release

Final Results for the Year Ended 31 January 2021

May 13, 2021

  • Press release

Notification of Full Year Results Date

May 6, 2021

  • Press release

ETX to receive two payments from Galapagos

Apr 23, 2021

  • Press release

Appointment of Chief Financial Officer

Mar 29, 2021

  • Press release

Change of Adviser

Mar 1, 2021

  • Press release

e-therapeutics to present at Shares Investor Evening

Feb 16, 2021

  • Press release

RNA Therapeutics Platform

Feb 1, 2021

  • Press release

COVID-19 Project Update

Dec 8, 2020

  • Press release

Interim Results for six months ended 31 July 2020

Oct 12, 2020

  • Press release

Appointment of Ali Mortazavi as CEO

Oct 12, 2020

RELENTLESS
CREATIVITY

London HQ

  • Floor 4, 4 Kingdom Street
    Paddington Central London W2 6BD

[LOCAL TIME]

Company

  • About
  • Our Approach
  • Pipeline
  • Investors
  • News
  • Careers
  • Leadership
  • Contact

© 2025 Tangram Therapeutics. Brand and website by UnitedUs. V1.2

  • Press Release Sign Up
  • Sitemap
  • Accessibility
  • Privacy
  • Tangram Therapeutics on LinkedIn
  • Tangram Therapeutics on X

OUR TRANSFORMATION INTO TANGRAM

Pioneering advancements in drug development takes steadfast persistence. A ceaseless evolution of understanding and innovation. That’s why E-Therapeutics has transformed into Tangram Therapeutics. The new brand embodies the expedited exploration needed to unlock life-transforming RNAi medicines faster. Breaking conventions of slow science, Tangram makes sense of patterns to find new answers. Our transformation into Tangram reveals the robust focus necessary for relentless medicine discovery.

Discover our new identity